We are live on
!
Find out more
BC
Birchview Capital Portfolio holdings
AUM
$176M
1-Year Est. Return
95.04%
This Fund
S&P 500
This Quarter
Est. Return
-4.06%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$128M
AUM Growth
-$13.8M
(-9.8%)
Cap. Flow
-$1.69M
Cap. Flow
% of AUM
-1.33%
Top 10 Holdings %
Top 10 Hldgs %
76.57%
Holding
60
New
3
Increased
5
Reduced
1
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$638K |
| 2 |
BLUE
bluebird bio
BLUE
|
+$578K |
| 3 |
Elutia
ELUT
|
+$536K |
| 4 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$358K |
| 5 |
Progyny
PGNY
|
+$297K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALBO
Albireo Pharma Inc
ALBO
|
+$2.53M |
| 2 |
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
|
+$1.5M |
| 3 |
Alphatec Holdings
ATEC
|
+$141K |
| 4 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
+$117K |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$102K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.37% |
| 2 | Energy | 3.59% |
| 3 | Consumer Staples | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GTHX
51
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $107K | 0.08% |
40,000
| – | – |
|
52
Nektar Therapeutics
NKTR
$2.39B
| $83K | 0.07% |
7,867
| – | – |
|
|
YTEN
53
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
| $52K | 0.04% |
781
| – | – |
|
54
Elicio Therapeutics
ELTX
$78.8M
| $32K | 0.03% |
5,439
| – | – |
|
|
AWH
55
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| $22K | 0.02% |
4,005
| – | – |
|
|
SIEN
56
DELISTED
Sientra, Inc.
SIEN
| – | – |
-4,000
| Closed | -$8K |
|
|
CNCE
57
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| – | – |
-20,000
| Closed | -$117K |
|
|
ALBO
58
DELISTED
Albireo Pharma Inc
ALBO
| – | – |
-117,000
| Closed | -$2.53M |
|
|
AVEO
59
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| – | – |
-100,000
| Closed | -$1.5M |
|
|
BHVN
60
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
-7,365
| Closed | -$102K |
|
Similar funds
RWA
BAM
TIM
LWM
PFA
DAM
AF
OA
Birchview Capital's Q1 2023 Portfolio in Review
As of Q1 2023, Birchview Capital held 60 positions worth $128M, down 9.8% from $142M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Birchview Capital's Q1 2023 filing shows 3 new, 5 increased, 1 reduced and 5 closed positions. Its largest new stake was Travere Therapeutics: 30,000 shares worth $675K. The largest sale was Albireo Pharma Inc, an estimated $2.53M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.
- Birchview Capital's largest Q1 2023 buy was Travere Therapeutics: 30,000 shares worth $675K.
- Birchview Capital added most to bluebird bio in Q1 2023, an estimated $578K increase.
- Birchview Capital's biggest Q1 2023 reduction was Alphatec Holdings, cutting an estimated $141K.
- Birchview Capital fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $2.53M.
- Birchview Capital's ten largest holdings make up 77% of its $128M portfolio in Q1 2023.
- Birchview Capital opened 3 new positions and closed 5 in Q1 2023.
- Birchview Capital's portfolio value fell 9.8% quarter-over-quarter to $128M.
Based on Birchview Capital's 13F filing for Q1 2023, filed 12 May 2023.